173
Participants
Start Date
January 31, 2007
Primary Completion Date
June 30, 2009
Study Completion Date
June 30, 2013
Belatacept
IV, IV Infusion, 5 mg/kg once every 28 days for one year
Cyclosporine A
Tablets, Oral, Trough of 100-250 ng/mL, 2\* daily for one year
Tacrolimus
Tablets, Oral, Trough of 5-10 ng/mL, 2\* daily for one year
Local Institution, Brussels
Local Institution, Buenos Aires
Local Institution, Rosario
Local Institution, Edegem
Local Institution, Parkville
Local Institution, Córdoba
Charite Berlin Mitte, Berlin
Local Institution, Df
Local Institution, Tlalpan, C P
Local Institution, Aguascalientes
Local Institution, Valencia
Medical College Of Wisconsin, Milwaukee
University Of Chicago, Chicago
Local Institution, Cuernavaca
Local Institution, Homburg/saar
Pharmacy, First Call Iv, Kenner
Tulane University Hospital & Clinic, New Orleans
Local Institution, Paris
Local Institution, San Luis Potosí City
Mayo Clinic Hospital, Phoenix
National Institute Of Transplantation, Los Angeles
California Institute Of Renal Research, San Diego
Local Institution, Pāladi
Local Institution, Nadiād
Local Institution, Kochi
Ucsf, San Francisco
University Of North Carolina School Of Medicine, Chapel Hill
Local Institution, Capital Federal
Local Institution, Santa Fe
Local Institution, Curitiba
Local Institution, Bonsucesso
Local Institution, Porto Alegre
Local Institution, Porto Alegre
Local Institution, São Paulo
Local Institution, Edmonton
Local Institution, Halifax
Local Institution, Hamilton
Local Institution, Saskatoon
Local Institution, Toulouse
Local Institution, Bydgoszcz
Local Institution, Szczecin
Local Institution, Warsaw
Local Institution, Barcelona
Local Institution, Barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY